BPC-157 10mg

BPC-157 10mg UK Research Peptide

BPC-157 10mg UK research peptide is a synthetic pentadecapeptide supplied for controlled in-vitro and laboratory research. Each vial contains 10mg of lyophilised BPC-157 and is accompanied by batch-specific quality documentation to support material identification, traceability and reproducible experimental work.

BPC-157 10mg UK Research Specifications

BPC-157 consists of 15 amino acids with the sequence GEPPPGKPADDAGLV. It has the molecular formula C62H98N16O22 and a molecular weight of approximately 1,419.53 g/mol. Its compact 15-amino-acid structure has attracted interest across a range of preclinical research fields, particularly those examining gastrointestinal biology, cellular signalling, angiogenesis and tissue-related laboratory models.

Published preclinical research has examined BPC-157 in experimental systems involving nitric oxide signalling, nitric oxide synthase activity, vascular endothelial growth factor pathways, fibroblast migration, inflammatory signalling and gastrointestinal mucosal biology. These findings are largely derived from animal, cellular and other preclinical research models. They must not be interpreted as evidence of safety, effectiveness or therapeutic benefit in humans.

BPC-157 10mg UK research material may be suitable for analytical investigations, assay development, concentration-response studies and multi-arm laboratory protocols where sufficient material from one documented batch is important for experimental consistency. The 10mg format can also support repeated analytical measurements or extended research programmes while reducing the variability that may arise from using several separate batches.

BPC-157 and TB-500 are sometimes examined within related tissue and cellular research fields, although their proposed laboratory mechanisms are distinct. BPC-157 has primarily been studied in relation to nitric oxide and vascular signalling pathways, while TB-500 is associated with actin binding and cytoskeletal dynamics. This distinction allows researchers to investigate the compounds as separate experimental variables rather than treating them as interchangeable materials.

BPC-157 has also been discussed alongside GHK-CU in cellular and extracellular-matrix research. BPC-157 is generally examined in nitric oxide, angiogenesis and migration-related models, whereas GHK-CU is a copper-binding peptide studied in relation to extracellular-matrix signalling and cellular remodelling. Compound selection should always be based on the specific aims, controls and analytical requirements of the proposed laboratory protocol.

Ascend Peptides UK provides batch-specific analytical documentation for BPC-157 10mg. The current product page links to independent Janoshik testing, allowing researchers to review the corresponding Certificate of Analysis. The listed quality documentation reports HPLC purity of at least 98% together with LC-MS molecular-identity confirmation.

Researchers should confirm that the batch or lot number shown on the supplied vial matches the batch number stated on the accompanying Certificate of Analysis. Analytical documentation should be reviewed before the material is introduced into any experimental system. Purity percentage alone does not establish molecular identity, so HPLC purity data should be considered alongside mass-spectrometry results and batch traceability.

BPC-157 10mg is supplied as a sealed lyophilised powder. Keep the vial protected from excessive heat, direct light and moisture. Storage and laboratory handling should follow the conditions printed on the current product label and batch-specific documentation. Researchers should use suitable protective equipment, sterile laboratory materials where required and an approved institutional handling procedure.

Any solvent selection, preparation method, concentration range or analytical protocol should be determined by an appropriately trained researcher according to the requirements of the specific in-vitro assay. Experimental records should document the product name, batch number, date received, storage conditions and all preparation steps to support reproducibility.

For further scientific background, researchers can consult the complete BPC-157 research guide published by Ascend Peptides UK. Information about analytical verification, Certificates of Analysis and independent laboratory testing is available through the Ascend Peptides UK quality-control and batch-verification pages.

WADA Status: BPC-157 is prohibited at all times under category S0, Non-Approved Substances, of the World Anti-Doping Agency Prohibited List.

DISCLAIMER: BPC-157 10mg is supplied strictly for in-vitro laboratory research and analytical use. It is not for human consumption, veterinary use, therapeutic use, diagnostic use or clinical administration. It is not an MHRA-licensed medicine and is not intended to diagnose, treat, cure or prevent any disease. Purchase and handling are restricted to appropriately trained individuals operating within a suitable research environment.